GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neuronetics Inc (NAS:STIM) » Definitions » Book Value per Share
中文

Neuronetics (Neuronetics) Book Value per Share : $1.18 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Neuronetics Book Value per Share?

Neuronetics's book value per share for the quarter that ended in Dec. 2023 was $1.18.

During the past 12 months, Neuronetics's average Book Value Per Share Growth Rate was -43.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -4.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -15.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Neuronetics was -4.10% per year. The lowest was -6.90% per year. And the median was -6.60% per year.

Neuronetics's current price is $3.75. Its book value per share for the quarter that ended in Dec. 2023 was $1.18. Hence, today's PB Ratio of Neuronetics is 3.19.

During the past 8 years, the highest P/B Ratio of Neuronetics was 15.94. The lowest was 0.57. And the median was 2.05.


Neuronetics Book Value per Share Historical Data

The historical data trend for Neuronetics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics Book Value per Share Chart

Neuronetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial 2.57 1.33 3.23 2.09 1.18

Neuronetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.09 1.70 1.58 1.31 1.18

Competitive Comparison of Neuronetics's Book Value per Share

For the Diagnostics & Research subindustry, Neuronetics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuronetics's PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Neuronetics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Neuronetics's PB Ratio falls into.



Neuronetics Book Value per Share Calculation

Neuronetics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(34.19-0.00)/29.09
=1.18

Neuronetics's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(34.19-0.00)/29.09
=1.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Neuronetics  (NAS:STIM) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Neuronetics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Neuronetics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuronetics (Neuronetics) Business Description

Traded in Other Exchanges
Address
3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Executives
Keith J Sullivan director, officer: President and CEO C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
William Andrew Macan officer: Sr. VP, GC, CCO and Secretary 24275 KATY FREEWAY, SUITE 600, KATY TX 77494
Stephen Furlong officer: CFO C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Robert Cascella director C/O HOLOGIC, INC., BEDFORD MA 01730
John K Bakewell director C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NO. BILLERICA MA 01862
Cannell Capital Llc 10 percent owner 245 MERIWETHER CIRCLE, ALTA WY 83414
Joseph H Capper director BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Bruce Joseph Shook director 162 CRICKET AVE, ARDMORE PA 19003
Megan Rosengarten director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Wilfred E Jaeger director C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Glenn P Muir director C/O HOLOGIC, INC., BEDFORD MA 01730
Gregory Harper officer: VP of Prod. Dev. & Operations C/O NEURONETICS, INC, 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Brian E Farley director 2200 ZANKER ROAD, SUITE F, SAN JOSE CA 95131
Daniel Guthrie officer: Chief Commercial Officer C/O NEURONETICS, INC, 322 PHOENIXVILLE PIKE, MALVERN PA 19355